Allogenica’s bioproduction process consists in:
Transferring therapeutic transgene to these immature cells (called pre-T cells)
2


Harvesting stem cell from healthy donors
1
Our commitment

We are committed to making T-cell therapies universally accessible by delivering treatments that are safer, more readily available to patients, and up to ten times less expensive to manufacture.
While cancer remains our primary focus, we also aim to address rare diseases and autoimmune disorders.
Inna MENKOVA, PhD
CEO and Co-founder of ALLOGENICA

WHY Allogenica
Our unique approach
4
After production, engineered pre-T cells are stored and ready to be delivered "off-the-shelf" when a patient needs them


Differentiate and expand the engineered pre-T cells at large scale in a bioreactor
3
Allogenica's unique expertise enables the differentiation of stem cells into immature precursor T cells. Allogenica's innovative vector allows these cells to be modified to produce a new generation of allogeneic T-cell therapies.
Allogenica’s most advanced drug candidate is expected to enter clinical trials in 2026.

Allogenica’s solution
Allogenica has developed unique worldwide expertise:
